Using ctDNA Blood Test for Earlier Detection and Treatment of Recurrence or Spread after Treatment for Stage 3 Colon Cancer identifier:
NCT03803553 (

Monitoring and treatment study for people who completed treatment for stage 3 colon cancer

Study Contact Information:

Name: Aparna Parikh, MD
Phone Number:617-724-4000
Email: [email protected]

About the Study

The usual care after a person with stage 3 colon cancer has had surgery and chemotherapy is to begin active surveillance. This is a time when no additional treatment is given, but instead patients have frequent imaging scans to see if their cancer has come back.

This study is looking at whether a blood test known as circulating tumor DNA (ctDNA) can find signs of remaining cancer or recurrence after treatment earlier than standard active surveillance. People in the study who have evidence of cancer in their ctDNA test may receive additional treatment based on their test results. All participants will receive close monitoring with imaging tests and blood tests. The goal of this study is to learn if using ctDNA and additional treatment improves outcomes in people after treatment for stage 3 colon cancer. Currently, testing with ctDNA and additional treatment based on ctDNA results is not part of standard of care. 

What the Study Involves

In order to participate, people in this study will receive a ctDNA test to see if there is any evidence of cancer. People will be assigned to different screening and treatment groups based on the results of their ctDNA test and their tumors. Participants will know which group they are in and what treatment they are receiving.

Based on the results of this pre-screening evaluation, participants will be placed into groups and will receive different treatments and follow up depending on which group they are in. Participants will be followed for 5 years.

For people whose pre-screening ctDNA test shows no evidence of cancer cells in the bloodstream (ctDNA negative):

For people whose pre-screening ctDNA test shows evidence of cancer cells in the bloodstream (ctDNA positive):

People who are ctDNA positive will be assigned to one of the groups below based on the presence or absence of additional tumor biomarkers.

Study Locations

Boston, Massachusetts
Massachusetts General Hospital
Contact: Aparna Parikh, MD       [email protected]   

Boston, Massachusetts
Dana Farber Cancer Institute
Contact: Marios Giannakis, MD       [email protected]   

This Study is Open To:

People who meet all of the following may be eligible:

This Study is Not Open To:

The following people may not be eligible:


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.